Conversely, neither treatment with buffer nor with all concentrations tested (0.01 – 100 ng/ml) of rLifADTD-AAA impaired the proliferation of CD4+ and CD8+ T cells (Figures 1, 2B). Here, CD4 is linked to triple-A syndrome.